FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Glenmark Pharmaceuticals Naproxen Sodium Tablets Recall

Naproxen Sodium Tablets, USP 550 mg Rx Only Manufactured by: Glenmark Pharmaceuticals Inc

Glenmark Pharmaceuticals Inc., USA · Mahwah, NJ

Risk level
Class II
Reported by FDA
Sep 29, 2021
Recall ID
D-0822-2021
Check your lot numberHow we source this data

Summary

Glenmark Pharmaceuticals recalled Naproxen Sodium Tablets starting Aug 27, 2021. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0822-2021 on Sep 29, 2021. Reason: CGMP Deviations. Status: Terminated.

Why it was recalled

CGMP Deviations

Product description

Naproxen Sodium Tablets, USP 550 mg Rx Only Manufactured by: Glenmark Pharmaceuticals Inc., USA 4147 Goldmine Road Monroe, NC 28110 Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430 a) 100 Tablets NDC 68462-179-01; b) 500 Tablets NDC 68462-179-05

Lot numbers, UPCs & expiration codes

Lots: a) 29190082 Exp. 09/30/2021; 29190083 Exp. 09/30/2021; 29190084 Exp. 10/31/2021; 29190085 Exp. 10/31/2021; 29200001 Exp. 12/31/2021; 29200003 Exp. 01/31/2022; 29200004 Exp. 01/31/2022; 29200005 Exp. 01/31/2022; 29200012 Exp. 02/28/2022; 29200013 Exp. 02/28/2022; b) 29200010 Exp. 02/28/2022

Where it was sold

Nationwide.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0822-2021
Classification
Class II
Status
Terminated
Recall initiated
Aug 27, 2021
FDA report date
Sep 29, 2021
Quantity
a) 31248 bottles; b) 300 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Glenmark Pharmaceuticals Inc., USA

Original FDA data

Every field from FDA enforcement report D-0822-2021, exactly as published.

Show all FDA fields
City
Mahwah
State
NJ
Status
Terminated
Country
United States
Event ID
88591
Address
750 Corporate Dr
Code information
Lots: a) 29190082 Exp. 09/30/2021; 29190083 Exp. 09/30/2021; 29190084 Exp. 10/31/2021; 29190085 Exp. 10/31/2021; 29200001 Exp. 12/31/2021; 29200003 Exp. 01/31/2022; 29200004 Exp. 01/31/2022; 29200005 Exp. 01/31/2022; 29200012 Exp. 02/28/2022; 29200013 Exp. 02/28/2022; b) 29200010 Exp. 02/28/2022
Postal code
07430-2009
Report date
Sep 29, 2021
Product type
Drugs
Recall number
D-0822-2021
Classification
Class II
Recalling firm
Glenmark Pharmaceuticals Inc., USA
Product quantity
a) 31248 bottles; b) 300 bottles
Termination date
Oct 4, 2023
Reason for recall
CGMP Deviations
Voluntary / mandated
Voluntary: Firm initiated
Product description
Naproxen Sodium Tablets, USP 550 mg Rx Only Manufactured by: Glenmark Pharmaceuticals Inc., USA 4147 Goldmine Road Monroe, NC 28110 Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430 a) 100 Tablets NDC 68462-179-01; b) 500 Tablets NDC 68462-179-05
Distribution pattern
Nationwide.
Recall initiation date
Aug 27, 2021
Initial firm notification
Letter
Center classification date
Sep 21, 2021

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0822-2021, published Sep 29, 2021. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls